RS65103B1 - Lečenje bolesnika sa klasičnom fabrijevom bolešću migalastatom - Google Patents

Lečenje bolesnika sa klasičnom fabrijevom bolešću migalastatom

Info

Publication number
RS65103B1
RS65103B1 RS20240081A RSP20240081A RS65103B1 RS 65103 B1 RS65103 B1 RS 65103B1 RS 20240081 A RS20240081 A RS 20240081A RS P20240081 A RSP20240081 A RS P20240081A RS 65103 B1 RS65103 B1 RS 65103B1
Authority
RS
Serbia
Prior art keywords
migalastat
salt
patient
patients
aspects
Prior art date
Application number
RS20240081A
Other languages
English (en)
Serbian (sr)
Inventor
Jay Barth
Elfrida Benjamin
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65494622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS65103(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of RS65103B1 publication Critical patent/RS65103B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RS20240081A 2018-02-06 2019-02-06 Lečenje bolesnika sa klasičnom fabrijevom bolešću migalastatom RS65103B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862626992P 2018-02-06 2018-02-06
PCT/US2019/016853 WO2019157056A1 (en) 2018-02-06 2019-02-06 Treatment of patients with classic fabry disease
EP19706182.3A EP3749308B1 (en) 2018-02-06 2019-02-06 Treatment of patients with classic fabry disease with migalastat

Publications (1)

Publication Number Publication Date
RS65103B1 true RS65103B1 (sr) 2024-02-29

Family

ID=65494622

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20240081A RS65103B1 (sr) 2018-02-06 2019-02-06 Lečenje bolesnika sa klasičnom fabrijevom bolešću migalastatom

Country Status (20)

Country Link
US (1) US20210038579A1 (enExample)
EP (2) EP4316589A3 (enExample)
JP (2) JP2021512896A (enExample)
KR (1) KR20200128675A (enExample)
CN (1) CN112203657A (enExample)
AR (1) AR114392A1 (enExample)
AU (2) AU2019217603A1 (enExample)
DK (1) DK3749308T3 (enExample)
ES (1) ES2969263T3 (enExample)
FI (1) FI3749308T3 (enExample)
HR (1) HRP20240025T1 (enExample)
HU (1) HUE064761T2 (enExample)
LT (1) LT3749308T (enExample)
PL (1) PL3749308T3 (enExample)
PT (1) PT3749308T (enExample)
RS (1) RS65103B1 (enExample)
SI (1) SI3749308T1 (enExample)
SM (1) SMT202400027T1 (enExample)
TW (1) TWI869336B (enExample)
WO (1) WO2019157056A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX351004B (es) 2006-05-16 2017-09-26 Nat Institutes Of Health Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
AU2018277756A1 (en) 2017-05-30 2020-01-23 Amicus Therapeutics, Inc. Methods of treating fabry patients having renal impairment
EP4717319A3 (en) 2018-02-06 2026-06-10 Amicus Therapeutics, Inc. Methods of treating fabry disease in pregnant patients
LT3840753T (lt) 2018-08-20 2024-11-11 Amicus Therapeutics, Inc. Migalastatas skirtas naudoti fabry ligos gydymo būdui, pacientams turintiems gla geno mutaciją
KR20220044560A (ko) 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
JP2024525760A (ja) * 2021-07-12 2024-07-12 アミカス セラピューティックス インコーポレイテッド 小児患者のファブリー病を治療する方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
MX351004B (es) * 2006-05-16 2017-09-26 Nat Institutes Of Health Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.
EP2142197A4 (en) 2007-03-30 2010-11-10 Amicus Therapeutics Inc METHOD FOR THE TREATMENT OF MORBUS FABRY WITH PHARMACOLOGICAL CHAPTERONES
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
EP3432882B1 (en) * 2016-03-22 2021-09-01 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having the g9331a mutation in the gla gene
WO2018017721A1 (en) * 2016-07-19 2018-01-25 Amicus Therapeutics, Inc. Treatment of fabry disease in ert-naïve and ert-experienced patients
EA202090242A1 (ru) * 2017-07-19 2020-05-26 Амикус Терапьютикс, Инк. Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов

Also Published As

Publication number Publication date
EP3749308A1 (en) 2020-12-16
SI3749308T1 (sl) 2024-03-29
HRP20240025T1 (hr) 2024-03-29
FI3749308T3 (fi) 2024-01-18
AU2025200074A1 (en) 2025-01-30
WO2019157056A8 (en) 2020-12-03
PT3749308T (pt) 2024-01-25
EP4316589A3 (en) 2024-04-24
KR20200128675A (ko) 2020-11-16
DK3749308T3 (da) 2024-01-22
US20210038579A1 (en) 2021-02-11
EP3749308B1 (en) 2023-10-25
TW201944998A (zh) 2019-12-01
AU2019217603A1 (en) 2020-09-24
SMT202400027T1 (it) 2024-03-13
CN112203657A (zh) 2021-01-08
CA3090499A1 (en) 2019-08-15
ES2969263T3 (es) 2024-05-17
TWI869336B (zh) 2025-01-11
PL3749308T3 (pl) 2024-03-25
EP4316589A2 (en) 2024-02-07
JP2024026080A (ja) 2024-02-28
TW202537622A (zh) 2025-10-01
HUE064761T2 (hu) 2024-04-28
AR114392A1 (es) 2020-09-02
LT3749308T (lt) 2024-02-12
WO2019157056A1 (en) 2019-08-15
JP2021512896A (ja) 2021-05-20

Similar Documents

Publication Publication Date Title
AU2023206175B2 (en) Treatment of fabry disease in ert-naïve and ert-experienced patients
US12414944B2 (en) Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene
EP3749308B1 (en) Treatment of patients with classic fabry disease with migalastat
TWI845479B (zh) 增強及/或穩定Fabry氏症患者之心臟功能之方法
RS67913B1 (sr) Postupci lečenja fabrijeve bolesti
WO2019017938A1 (en) TREATMENT OF FABRY'S DISEASE IN PATIENTS WITHOUT SUBSTITUTED ENZYMATIC THERAPY (TES) AND PATIENTS SUBJECT TO TES
RS66410B1 (sr) Upotreba migalostata u smanjenju rizika od cerebrovaskularnog događaja kod pacijenata sa fabrijevom bolešću
RS66376B1 (sr) Lečenje fabri pacijenata koji imaju određene mutacije
CA3090499C (en) Use of migalastat for the treatment of patients with classic fabry disease
HK40106025A (en) Treatment of patients with classic fabry disease
TW201907921A (zh) 治療ert初治的和已經歷ert的患者中之法布瑞氏症